#USA #New York #Class Action #Gross Law Firm #ESSA Pharma

Investor Alert: ESSA Pharma Inc. Class Action Lawsuit Reminder

The Gross Law Firm has recently issued an important notice for investors in ESSA Pharma Inc. (NASDAQ: EPIX), calling attention to a pending class action lawsuit. This notice primarily aims to inform shareholders who acquired shares during the specified class period to take necessary actions before the impending deadline of March 25, 2025.

Details of the Class Action

Shareholders who purchased shares from December 12, 2023, until October 31, 2024, are being urged to reach out to the firm regarding their potential role as lead plaintiffs. It’s crucial to note that registering as a lead plaintiff is not a prerequisite to participate in any recovery related to this case.

The core allegations of the lawsuit raise significant concerns about the accuracy of statements made by the company regarding masofaniten, a treatment purported to be effective in combination with enzalutamide for prostate cancer. The complaint alleges that the defendants misrepresented the efficacy of this combination, leading investors to believe it was more effective than it potentially is. Specifically, the firm argues that:
1. Efficacy Misrepresentation: The M-E Combination Study appears unlikely to meet its primary endpoint, contradicting company claims that had given shareholders optimism about its prospects.
2. Exaggerated Prospects: The lawsuit suggests that the actual clinical and regulatory potential of masofaniten has been overstated to investors, resulting in misleading public statements about its ability to treat prostate cancer effectively.
3. Shareholder Impact: As these statements are alleged to have misled investors, the legal action aims to hold the company accountable for any losses incurred due to this misinformation.

Next Steps for Investors

Shareholders who find themselves within the specified class period are encouraged to register promptly. By doing so, they will benefit from the Gross Law Firm’s monitoring software, which will keep them updated on the case’s progress. It's important to understand that, while the deadline to seek lead plaintiff status is set for March 25, 2025, participation in the case bears no financial obligation, ensuring that those involved can maintain their rights without risking additional liabilities.

Importance of Legal Representation

The Gross Law Firm stands out as a nationally recognized authority in matters pertaining to class actions, particularly when they involve investor protection against fraudulent behaviors and misleading practices within corporations. Their unwavering commitment focuses on recovering losses sustained through deceptive statements and ensuring accountability in corporate conduct.

In conclusion, investors of ESSA Pharma are strongly encouraged to consider their options and take necessary actions timely to safeguard their interests in light of the upcoming legal proceedings. More information is available through the firm's dedicated portal where interested parties can easily submit their information for monitoring.

Contact Information

For more details or to register, shareholders are urged to visit the following link to access the submission form: ESSA Pharma Loss Submission. You can also reach out to The Gross Law Firm directly at their New York office at 15 West 38th Street, 12th Floor, New York, NY, 10018 or via email at [email protected] for personalized queries.